Language: Mandarin, English
Department：Director of Gene & Cell Lab
Chief Scientist of ReLife International Medical Center
Researcher, Academy of Military Medical Science, Chinese People’s Liberation Army – PLA
Dr. Wu has focused on stem cell research, immunological cell research as well as clinical research for decades. He developed cell culture kits for cytokine-induced killer (CIK) cells, dendritic cells (DCs) and natural killer (NK) cells.
He took charge of the Chinese national support 863 projects “Pre-clinical Study on Bio-therapy of Malignant Tumor with Human Wild-Type p-53, GM-CSF and B7-1 Genes Mediated by Recombinant Adenovirus Vector” (2001AA217041) and “Gene Therapy with Human Hepatocyte Growth Factor for Treating Ischemic Vascular Disease and Pathological Scar (2001AA217061, 2003AA216081).
The “Recombinant Adenovirus – Hepatocyte Growth Factor Injectors” and “Recombinant Plasmid – Hepatocyte Growth Factor Injectors” he developed were respectively approved by China Food and Drug Administration with Type I new drug clinical approval of biological product in 2005 and 2007 (Approval No. 2005L01181, 2007L01482). The “Recombinant Adenovirus – Hepatocyte Growth Factor Injectors” received stage II drug clinical trial approval (Approval No. 2009L01499).